Assessment of Zegerid on Esophageal pH in Patients With Barrett's Esophagus
Status:
Terminated
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to assess how safe, effective (how well it works), and
tolerable (to put up with) the drug Zegerid is in reducing reflux episodes in patients who
have both gastroesophageal reflux disease (GERD) and Barrett's esophagus. Zegerid has been
approved by the US Food and Drug Administration (FDA) for the treatment of GERD. The
investigators hope to learn the effectiveness of Zegerid for reducing the amount of acid
reflux patients are experiencing in the esophagus (swallowing pipe).
Phase:
N/A
Details
Lead Sponsor:
Stanford University
Treatments:
Omeprazole Omeprazole, sodium bicarbonate drug combination Proton Pump Inhibitors